[
    [
        {
            "time": "2023-10-05",
            "original_text": "AbbVie (ABBV) Stock Moves -0.55%: What You Should Know",
            "features": {
                "keywords": [
                    "AbbVie",
                    "stock moves",
                    "-0.55%"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Stock Moves -0.55%: What You Should Know",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study",
            "features": {
                "keywords": [
                    "Lilly",
                    "Mirikizumab",
                    "Crohn's Disease",
                    "efficacy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr",
            "features": {
                "keywords": [
                    "NIH",
                    "AbbVie",
                    "Boehringer Ingelheim",
                    "remdesivir",
                    "drug trial"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "research"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Coronavirus update: J&J and Eli Lilly trials hit pause as US doubles down on antibody therapies",
            "features": {
                "keywords": [
                    "Coronavirus",
                    "J&J",
                    "Eli Lilly",
                    "trials paused",
                    "antibody therapies"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Coronavirus update: J&J and Eli Lilly trials hit pause as US doubles down on antibody therapies",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]